Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
28
XTLB Quote, Financials, Valuation and Earnings
Last price:
$0.78
Seasonality move
:
-7.42%
Day range:
$0.74 - $0.80
52-week range:
$0.53 - $2.57
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.79x
P/B ratio:
1.26x
Volume:
8.4K
Avg. volume:
84.7K
1-year change:
-44.74%
Market cap:
$6.8M
Revenue:
$453.1K
EPS (TTM):
-$0.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
|
BLRX
BioLineRx Ltd.
|
$492K | -$0.77 | -95.85% | -49.07% | $20.33 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
CGEN
Compugen Ltd.
|
$14.3M | $0.14 | -100% | -2.83% | $5.80 |
|
EVGN
Evogene Ltd.
|
$275K | -$0.26 | -82.93% | -68.8% | $2.50 |
|
PLUR
Pluri, Inc.
|
$638K | -$0.65 | 316.67% | -79.86% | $12.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XTLB
XTL Biopharmaceuticals Ltd.
|
$0.78 | -- | $6.8M | -- | $0.00 | 0% | 13.79x |
|
BLRX
BioLineRx Ltd.
|
$2.81 | $20.33 | $12.2M | -- | $0.00 | 0% | 0.77x |
|
CANF
Can-Fite BioPharma Ltd.
|
$5.00 | $2.50 | $6.5M | -- | $0.00 | 0% | 27.89x |
|
CGEN
Compugen Ltd.
|
$2.00 | $5.80 | $187.1M | 55.83x | $0.00 | 0% | 2.57x |
|
EVGN
Evogene Ltd.
|
$0.85 | $2.50 | $7.4M | -- | $0.00 | 0% | 1.19x |
|
PLUR
Pluri, Inc.
|
$3.53 | $12.00 | $35.5M | -- | $0.00 | 0% | 21.56x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XTLB
XTL Biopharmaceuticals Ltd.
|
2.86% | 0.006 | 1.28% | 0.75x |
|
BLRX
BioLineRx Ltd.
|
36.81% | 2.584 | 69.17% | 1.84x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 1.072 | -- | -- |
|
CGEN
Compugen Ltd.
|
2.8% | 2.063 | 2.07% | 6.45x |
|
EVGN
Evogene Ltd.
|
68.82% | 1.837 | 9.67% | 4.01x |
|
PLUR
Pluri, Inc.
|
172.93% | 0.067 | 98.32% | 0.40x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -$764K | -33.97% | -34.34% | -283.95% | -- |
|
BLRX
BioLineRx Ltd.
|
$225K | -$2.2M | -9.37% | -18.74% | -516.85% | -$2.1M |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$63.8M | $56M | 54.64% | 57.22% | 84.43% | -- |
|
EVGN
Evogene Ltd.
|
-$126K | -$2.7M | -57.78% | -66.95% | -870.19% | -$3.8M |
|
PLUR
Pluri, Inc.
|
-$43K | -$6.5M | -93.31% | -5662.45% | -3285.86% | -$5.7M |
XTL Biopharmaceuticals Ltd. vs. Competitors
-
Which has Higher Returns XTLB or BLRX?
BioLineRx Ltd. has a net margin of -341.36% compared to XTL Biopharmaceuticals Ltd.'s net margin of -228.81%. XTL Biopharmaceuticals Ltd.'s return on equity of -34.34% beat BioLineRx Ltd.'s return on equity of -18.74%.
Company Gross Margin Earnings Per Share Invested Capital XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M BLRXBioLineRx Ltd.52.45% -$0.22 $30.9M -
What do Analysts Say About XTLB or BLRX?
XTL Biopharmaceuticals Ltd. has a consensus price target of --, signalling upside risk potential of 3770.97%. On the other hand BioLineRx Ltd. has an analysts' consensus of $20.33 which suggests that it could grow by 623.61%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than BioLineRx Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than BioLineRx Ltd..
Company Buy Ratings Hold Ratings Sell Ratings XTLBXTL Biopharmaceuticals Ltd.0 0 0 BLRXBioLineRx Ltd.2 0 0 -
Is XTLB or BLRX More Risky?
XTL Biopharmaceuticals Ltd. has a beta of 1.193, which suggesting that the stock is 19.26% more volatile than S&P 500. In comparison BioLineRx Ltd. has a beta of 1.309, suggesting its more volatile than the S&P 500 by 30.875%.
-
Which is a Better Dividend Stock XTLB or BLRX?
XTL Biopharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioLineRx Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XTL Biopharmaceuticals Ltd. pays -- of its earnings as a dividend. BioLineRx Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XTLB or BLRX?
XTL Biopharmaceuticals Ltd. quarterly revenues are $162K, which are smaller than BioLineRx Ltd. quarterly revenues of $429K. XTL Biopharmaceuticals Ltd.'s net income of -$553K is higher than BioLineRx Ltd.'s net income of -$981.6K. Notably, XTL Biopharmaceuticals Ltd.'s price-to-earnings ratio is -- while BioLineRx Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XTL Biopharmaceuticals Ltd. is 13.79x versus 0.77x for BioLineRx Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XTLBXTL Biopharmaceuticals Ltd.13.79x -- $162K -$553K BLRXBioLineRx Ltd.0.77x -- $429K -$981.6K
-
Which has Higher Returns XTLB or CANF?
Can-Fite BioPharma Ltd. has a net margin of -341.36% compared to XTL Biopharmaceuticals Ltd.'s net margin of --. XTL Biopharmaceuticals Ltd.'s return on equity of -34.34% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About XTLB or CANF?
XTL Biopharmaceuticals Ltd. has a consensus price target of --, signalling upside risk potential of 3770.97%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 900%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than Can-Fite BioPharma Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than Can-Fite BioPharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings XTLBXTL Biopharmaceuticals Ltd.0 0 0 CANFCan-Fite BioPharma Ltd.1 1 0 -
Is XTLB or CANF More Risky?
XTL Biopharmaceuticals Ltd. has a beta of 1.193, which suggesting that the stock is 19.26% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 1.011, suggesting its more volatile than the S&P 500 by 1.09%.
-
Which is a Better Dividend Stock XTLB or CANF?
XTL Biopharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XTL Biopharmaceuticals Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XTLB or CANF?
XTL Biopharmaceuticals Ltd. quarterly revenues are $162K, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. XTL Biopharmaceuticals Ltd.'s net income of -$553K is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, XTL Biopharmaceuticals Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XTL Biopharmaceuticals Ltd. is 13.79x versus 27.89x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XTLBXTL Biopharmaceuticals Ltd.13.79x -- $162K -$553K CANFCan-Fite BioPharma Ltd.27.89x -- -- --
-
Which has Higher Returns XTLB or CGEN?
Compugen Ltd. has a net margin of -341.36% compared to XTL Biopharmaceuticals Ltd.'s net margin of 84.43%. XTL Biopharmaceuticals Ltd.'s return on equity of -34.34% beat Compugen Ltd.'s return on equity of 57.22%.
Company Gross Margin Earnings Per Share Invested Capital XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M CGENCompugen Ltd.94.75% -- $105.7M -
What do Analysts Say About XTLB or CGEN?
XTL Biopharmaceuticals Ltd. has a consensus price target of --, signalling upside risk potential of 3770.97%. On the other hand Compugen Ltd. has an analysts' consensus of $5.80 which suggests that it could grow by 190%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than Compugen Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings XTLBXTL Biopharmaceuticals Ltd.0 0 0 CGENCompugen Ltd.5 0 0 -
Is XTLB or CGEN More Risky?
XTL Biopharmaceuticals Ltd. has a beta of 1.193, which suggesting that the stock is 19.26% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.896, suggesting its more volatile than the S&P 500 by 189.647%.
-
Which is a Better Dividend Stock XTLB or CGEN?
XTL Biopharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XTL Biopharmaceuticals Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XTLB or CGEN?
XTL Biopharmaceuticals Ltd. quarterly revenues are $162K, which are smaller than Compugen Ltd. quarterly revenues of $67.3M. XTL Biopharmaceuticals Ltd.'s net income of -$553K is lower than Compugen Ltd.'s net income of $56.8M. Notably, XTL Biopharmaceuticals Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XTL Biopharmaceuticals Ltd. is 13.79x versus 2.57x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XTLBXTL Biopharmaceuticals Ltd.13.79x -- $162K -$553K CGENCompugen Ltd.2.57x 55.83x $67.3M $56.8M
-
Which has Higher Returns XTLB or EVGN?
Evogene Ltd. has a net margin of -341.36% compared to XTL Biopharmaceuticals Ltd.'s net margin of -874.68%. XTL Biopharmaceuticals Ltd.'s return on equity of -34.34% beat Evogene Ltd.'s return on equity of -66.95%.
Company Gross Margin Earnings Per Share Invested Capital XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M EVGNEvogene Ltd.-40.39% $0.44 $19.8M -
What do Analysts Say About XTLB or EVGN?
XTL Biopharmaceuticals Ltd. has a consensus price target of --, signalling upside risk potential of 3770.97%. On the other hand Evogene Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 195.02%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than Evogene Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than Evogene Ltd..
Company Buy Ratings Hold Ratings Sell Ratings XTLBXTL Biopharmaceuticals Ltd.0 0 0 EVGNEvogene Ltd.1 0 0 -
Is XTLB or EVGN More Risky?
XTL Biopharmaceuticals Ltd. has a beta of 1.193, which suggesting that the stock is 19.26% more volatile than S&P 500. In comparison Evogene Ltd. has a beta of 1.362, suggesting its more volatile than the S&P 500 by 36.219%.
-
Which is a Better Dividend Stock XTLB or EVGN?
XTL Biopharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evogene Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XTL Biopharmaceuticals Ltd. pays -- of its earnings as a dividend. Evogene Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XTLB or EVGN?
XTL Biopharmaceuticals Ltd. quarterly revenues are $162K, which are smaller than Evogene Ltd. quarterly revenues of $312K. XTL Biopharmaceuticals Ltd.'s net income of -$553K is higher than Evogene Ltd.'s net income of -$2.7M. Notably, XTL Biopharmaceuticals Ltd.'s price-to-earnings ratio is -- while Evogene Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XTL Biopharmaceuticals Ltd. is 13.79x versus 1.19x for Evogene Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XTLBXTL Biopharmaceuticals Ltd.13.79x -- $162K -$553K EVGNEvogene Ltd.1.19x -- $312K -$2.7M
-
Which has Higher Returns XTLB or PLUR?
Pluri, Inc. has a net margin of -341.36% compared to XTL Biopharmaceuticals Ltd.'s net margin of -3470.71%. XTL Biopharmaceuticals Ltd.'s return on equity of -34.34% beat Pluri, Inc.'s return on equity of -5662.45%.
Company Gross Margin Earnings Per Share Invested Capital XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M PLURPluri, Inc.-21.72% -$0.71 $25.4M -
What do Analysts Say About XTLB or PLUR?
XTL Biopharmaceuticals Ltd. has a consensus price target of --, signalling upside risk potential of 3770.97%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 239.93%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than Pluri, Inc., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than Pluri, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XTLBXTL Biopharmaceuticals Ltd.0 0 0 PLURPluri, Inc.1 0 0 -
Is XTLB or PLUR More Risky?
XTL Biopharmaceuticals Ltd. has a beta of 1.193, which suggesting that the stock is 19.26% more volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.7%.
-
Which is a Better Dividend Stock XTLB or PLUR?
XTL Biopharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XTL Biopharmaceuticals Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XTLB or PLUR?
XTL Biopharmaceuticals Ltd. quarterly revenues are $162K, which are smaller than Pluri, Inc. quarterly revenues of $198K. XTL Biopharmaceuticals Ltd.'s net income of -$553K is higher than Pluri, Inc.'s net income of -$6.9M. Notably, XTL Biopharmaceuticals Ltd.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XTL Biopharmaceuticals Ltd. is 13.79x versus 21.56x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XTLBXTL Biopharmaceuticals Ltd.13.79x -- $162K -$553K PLURPluri, Inc.21.56x -- $198K -$6.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 4
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Buy
54
KORU alert for Mar 4
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 5.43% over the past day.
Sell
40
PSIX alert for Mar 4
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
